Levine Children's Hospital
Our world revolves around children.

The Torrence E. Hemby, Jr.
Pediatric Hematology and Oncology Center

COG Phase III Ewing Sarcoma

Protocol Title

AEWS1031 A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

COG	Principal Investigator	Study Coordinator
Children's Oncology Group	Joel Kaplan, DO, MPH joel.kaplan@carolinashealthcare.org	Wendy Bissette, RN, BS

Status

Active

Key Inclusion Criteria*

- Age ≤ 50 years at diagnosis
- Patients with newly diagnosed, biopsy confirmed, extracranial, non-metastatic Ewing sarcoma or PNET of bone or soft tissue
  - For the purpose of this study, chest wall tumors with ipsilateral pleural effusions, ipsilateral positive pleural fluid cytology or ipsilateral pleural based secondary tumor nodules will be considered localized disease
  - Patients with regional node involvement, based on clinical suspicion confirmed by pathologic documentation are considered to be non-metastatic
  - Tumors arising in the bony skull (extra-dural) are considered to be extracranial
- Adequate renal, liver, and cardiac function

Key Exclusion Criteria*

- Prior chemotherapy or radiation therapy
- Evidence of metastatic disease
- Patients whose tumors arise in the intra-dural soft tissue
- Pregnant or breastfeeding females

Therapies

Chemotherapy

- Vincristine
- Doxorubicin
- Cyclophosphamide
- Topotecan
- Ifosfamide
- Etoposide
- Mesna
- Dexrazoxane

Radiation

Surgery

Referrals

Please contact for referrals and/or study information:
Wendy Bissette, RN
Ph 704-355-9081
wendy.bissette@carolinashealthcare.org

* Additional criteria apply.